Luminous Medical
Total Raised
$32.5MInvestors Count
6Deal Terms
2Funding, Valuation & Revenue
3 Fundings
Luminous Medical'slatest funding roundwas aSeries B for $23.5MonMarch 17, 2008.
Luminous Medical'svaluationinNovember 2005was$22.59M.
Luminous Medical's latestpost-money valuationis fromMarch 2008.
Sign up for a free trialto see Luminous Medical's valuations in March 2008 and more.
Date |
Round |
Amount |
Investors |
Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.
|
Revenue |
Sources |
---|---|---|---|---|---|---|
3/17/2008 |
Series B |
$23.5M |
||||
11/24/2005 |
Series A |
$22.59M |
||||
|
Other Investors |
Date |
3/17/2008 |
11/24/2005 |
|
---|---|---|---|
Round |
Series B |
Series A |
Other Investors |
Amount |
$23.5M |
||
Investors |
|||
Valuation |
$22.59M |
||
Revenue |
|||
Sources |
This profile has not been claimed.
You're more than your latest funding, tell our customers your company's story.
Luminous MedicalDeal Terms
2 Deal Terms
Luminous Medical'sdeal structure is available for2fundingrounds, including theirSeries BfromMarch 17, 2008.
Round |
Series B |
Series A |
---|---|---|
Funding Date |
||
Pre-Money Valuation |
||
Post-Money Valuation |
||
Amount Raised |
||
Shares Authorized |
||
Issuance Price |
||
Dividend Rate |
||
Liquidation Preferences |
||
清算價格 |
||
Participation |
||
Conversion Price |
||
Anti Dilution |
||
General Voting |
||
Board Voting |
||
Par Value |
Round |
Funding Date |
Pre-Money Valuation |
Post-Money Valuation |
Amount Raised |
Shares Authorized |
Issuance Price |
Dividend Rate |
Liquidation Preferences |
清算價格 |
Participation |
Conversion Price |
Anti Dilution |
General Voting |
Board Voting |
Par Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B |
|||||||||||||||
Series A |
Luminous Medical Investors
6 Investors
Luminous Medical has6 investors.De Novo Venturesinvested in Luminous Medical'sSeries B funding round.
First funding |
Last Funding |
Investor |
Rounds |
Board Seats |
Type |
Location |
---|---|---|---|---|---|---|
11/24/2005 |
3/17/2008 |
2
Series A, Series B (2008)
|
F. Watkins |
Venture Capital |
California |
|
Venture Capital |
California |
|||||
Venture Capital |
Missouri |
|||||
Private Equity |
Illinois |
|||||
Venture Capital |
California |
First funding |
11/24/2005 |
||||
---|---|---|---|---|---|
Last Funding |
3/17/2008 |
||||
Investor |
|||||
Rounds |
2
Series A, Series B (2008)
|
||||
Board Seats |
F. Watkins |
||||
Type |
Venture Capital |
Venture Capital |
Venture Capital |
Private Equity |
Venture Capital |
Location |
California |
California |
Missouri |
Illinois |
California |
Compare Luminous Medical to Competitors
Arkal Medical is developing a continuous blood glucose sensor for diabetes.
Bay Area Digital is a company that received a SBIR Phase I grant for a project entitled: Talking Blood Glucose Meter with full Accessibility for Blind, Visually and Cognitively Impaired. Their Project addresses a crisis in the lack of effective glucose monitoring equipment for visually and cognitively impaired diabetics. The proposal thoroughly examines the technical and commercial feasibility of developing innovative technology that enables such patients to reliably use information provided by a state-of-the-art blood glucose meter, using speech output that is coupled with a commercially developed meter. There are currently no state-of-the-art or best-of-breed blood glucose meter systems available in the U.S. market with speech capabilities for use by the cognitively, visually impaired or blind community. The development of such a meter will positively impact the self-management of diabetes mellitus, improving quality of life and clinical outcomes for patients and preventing the development of secondary complications and provide an opportunity to impact a major health problem affecting millions of U.S. citizens.
Vytrace公司正在開發一個新的重要的care monitor to monitor glucose at the bedside of critically ill patients in the Intensive Care Unit. The product is designed specifically for patients in the ICU. Vytrace Corporation is developing a new critical care monitor to monitor glucose at the bedside of critically ill patients in the Intensive Care Unit. The product is designed specifically for patients in the ICU. This is not a consumer product for diabetic glucose monitoring. They also are exploring other analytes that may be monitored with their sensor technology. Vytrace Corporation has a highly accurate bedside monitor that automatically and continuously monitors blood glucose via a fiberoptic catheter with a photonic crystal sensor on the tip.
Located in Hanover, NH and San Francisco, CA, Novoculi is a medical device company focused on developing a non-invasive, optical blood glucose monitor. Novoculi's Noninvasive Blood Glucose Monitor aims to build on physiologically demonstrated optical phenomena which forms the basis for Novoculi's technology. Novoculi hopes to leverage its technology to develop a non-invasive blood glucose monitor which will allow its patient population to better manage their blood glucose without a painful finger stick.
Advanced BioSensors is developing a miniaturized blood glucose sensor for use in the treatment of diabetes.
Vytrace Corporation (fka Glucose Sensing Technologies) is developing a new critical care monitor to monitor glucose at the bedside of critically ill patients in the Intensive Care Unit. The product is designed specifically for patients in the ICU. This is not a consumer product for diabetic glucose monitoring. They also are exploring other analytes that may be monitored with their sensor technology. Vytrace Corporation has a highly accurate bedside monitor that automatically and continuously monitors blood glucose via a fiberoptic catheter with a photonic crystal sensor on the tip.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.